Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy
Tracking # 20-1354258
Course overview
Discover the latest advances in diagnosing and treating hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM) in this essential on-demand course. Gain practical strategies for early detection, explore emerging therapies, and review real-world patient cases. Learn to recognize key clinical features, navigate genetic testing, and optimize treatment decisions for this now-treatable disease. Enroll today to improve patient outcomes.
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Practitioner
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
Registered Nurse Practitioner
District of Columbia Board of Nursing
Clinical Nurse Specialist
Licensed Practical Nurse
Nurse Practitioner
Registered Nurse
Florida Board of Nursing - Certified Nursing Assistants
Certified Nursing Assistant
Georgia Board of Nursing
Licensed Practical Nurse
Registered Professional Nurse
Kansas State Board of Nursing
Clinical Nurse Specialist
Licensed Practical Nurse
Nurse Practitioner
Registered Nurse
New Hampshire Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
New Mexico Board of Nursing
Certified Nurse Practitioner
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
North Dakota Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Tennessee Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Wyoming Board of Nursing
Certified Nurse Midwife
Certified Nurse Practitioner
Certified Nurse Specialist
Certified Nursing Assistant
Licensed Practical Nurse
Registered Nurse
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
Mathew Maurer, MD, discloses that he has served on an advisory board or panel for Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer; and that he has received grants/research support from Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer.
The i3 Health planners, reviewers, and managers have nothing to disclose.
i3 Health has mitigated all relevant financial relationships.